X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SUN PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SUN PHARMA PANACEA BIOTECH/
SUN PHARMA
 
P/E (TTM) x 172.6 23.6 731.6% View Chart
P/BV x 3.8 3.4 111.2% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PANACEA BIOTECH   SUN PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
SUN PHARMA
Mar-17
PANACEA BIOTECH/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs149842 17.7%   
Low Rs82572 14.4%   
Sales per share (Unadj.) Rs84.1131.6 63.9%  
Earnings per share (Unadj.) Rs-18.332.7 -56.0%  
Cash flow per share (Unadj.) Rs-6.738.0 -17.6%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs83.7152.7 54.8%  
Shares outstanding (eoy) m61.252,399.26 2.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.45.4 25.5%   
Avg P/E ratio x-6.321.6 -29.2%  
P/CF ratio (eoy) x-17.218.6 -92.6%  
Price / Book Value ratio x1.44.6 29.8%  
Dividend payout %010.7 0.0%   
Avg Mkt Cap Rs m7,0741,696,877 0.4%   
No. of employees `0002.817.5 15.7%   
Total wages/salary Rs m1,44949,023 3.0%   
Avg. sales/employee Rs Th1,874.118,028.3 10.4%   
Avg. wages/employee Rs Th527.02,798.8 18.8%   
Avg. net profit/employee Rs Th-407.74,479.5 -9.1%   
INCOME DATA
Net Sales Rs m5,154315,784 1.6%  
Other income Rs m1006,232 1.6%   
Total revenues Rs m5,254322,016 1.6%   
Gross profit Rs m-766100,893 -0.8%  
Depreciation Rs m71112,648 5.6%   
Interest Rs m1,5033,998 37.6%   
Profit before tax Rs m-2,88190,479 -3.2%   
Minority Interest Rs m110-   
Prior Period Items Rs m-699 -5.7%   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m1712,116 0.1%   
Profit after tax Rs m-1,12178,462 -1.4%  
Gross profit margin %-14.931.9 -46.5%  
Effective tax rate %-0.613.4 -4.4%   
Net profit margin %-21.824.8 -87.6%  
BALANCE SHEET DATA
Current assets Rs m3,810329,537 1.2%   
Current liabilities Rs m8,365178,870 4.7%   
Net working cap to sales %-88.447.7 -185.2%  
Current ratio x0.51.8 24.7%  
Inventory Days Days15679 197.1%  
Debtors Days Days6783 80.8%  
Net fixed assets Rs m14,480204,766 7.1%   
Share capital Rs m612,399 2.6%   
"Free" reserves Rs m903363,997 0.2%   
Net worth Rs m5,127366,397 1.4%   
Long term debt Rs m5,83214,361 40.6%   
Total assets Rs m19,433614,102 3.2%  
Interest coverage x-0.923.6 -3.9%   
Debt to equity ratio x1.10 2,901.9%  
Sales to assets ratio x0.30.5 51.6%   
Return on assets %2.013.4 14.6%  
Return on equity %-21.921.4 -102.1%  
Return on capital %3.624.8 14.6%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53944,118 3.5%   
Fx outflow Rs m94224,484 3.8%   
Net fx Rs m59719,634 3.0%   
CASH FLOW
From Operations Rs m59970,822 0.8%  
From Investments Rs m-438-42,216 1.0%  
From Financial Activity Rs m-303-22,854 1.3%  
Net Cashflow Rs m-1416,107 -2.3%  

Share Holding

Indian Promoters % 74.5 63.7 117.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 5.1 11.7%  
FIIs % 1.3 23.0 5.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 8.3 284.3%  
Shareholders   10,259 133,026 7.7%  
Pledged promoter(s) holding % 35.1 0.5 6,617.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 22, 2018 09:07 AM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS